Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 285
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT04545515 | A Study Evaluating the Long-term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis (CF) Particpants 6 Years and Older and F/MF Genotypes | ||
| NCT04043806 | A Study Evaluating the Long-term Safety of VX-445 Combination Therapy | ||
| NCT04058366 | Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy | ||
| NCT02514473 | A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation | ||
| NCT01459913 | Efficacy of a 12-Week Regimen of Telaprevir, Pegylated Interferon, and Ribavirin in Treatment-Naive and Prior Relapser Subjects With Interleukin28B (IL28B) CC Genotype | ||
| NCT05558410 | Evaluation of Efficacy and Safety of Suzetrigine for Acute Pain After an Abdominoplasty | ||
| NCT03304028 | MUCOviscidose EXacerbation Outils Connectés Education Thérapeutique | ||
| NCT03206749 | A Study to Evaluate Efficacy and Safety of VX-150 in Subjects With Acute Pain Following Bunionectomy | ||
| NCT03278314 | Tezacaftor/Ivacaftor Combination Therapy Expanded Access Program for Patients 12 Years of Age and Older With Cystic Fibrosis | ||
| NCT06628908 | Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy | ||
| NCT01241760 | VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naïve Participants With Genotype 1 Chronic Hepatitis C Virus Infection | ||
| NCT00923728 | A Phase I Trial of AVN944, an IMPDH Inhibitor, in Adults With Advanced Stage Solid Tumors | ||
| NCT03655678 | A Safety and Efficacy Study Evaluating CTX001 in Participants With Transfusion-Dependent β-Thalassemia | ||
| NCT03525574 | A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy | ||
| NCT06832410 | An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant | ||
| NCT06861413 | A Phase 1 Study to Evaluate the Relative Bioavailability of a VX-828 Tablet Formulation | ||
| NCT02823470 | A Pilot Study to Evaluate the Use of Smart Adherence Technology to Measure Lumacaftor/Ivacaftor Adherence in CF Subjects Homozygous for the F508del CFTR Mutation | ||
| NCT01590459 | 24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate | ||
| NCT06696443 | Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN) | ||
| NCT05356195 | Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT) | ||
| NCT05955872 | A Study Evaluating the Relative Bioavailability and Food Effect of a Tablet Formulation of VX-147 | ||
| NCT05882357 | Evaluation of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis (CF) Participants 12 to Less Than 24 Months of Age | ||
| NCT02934698 | An Efficacy and Safety Study of Ivacaftor in Patients With Cystic Fibrosis and Two Splicing Mutations | ||
| NCT00389298 | A Proof-of-concept Study of VCH-759 for the Treatment of Hepatitis C-infection. | ||
| NCT02722057 | A Study to Confirm the Long-term Safety and Effectiveness of Kalydeco in Patients With Cystic Fibrosis Who Have an R117H-CFTR Mutation, Including Pediatric Patients | ||
| NCT01501383 | A Study to Evaluate the Efficacy and Safety of VX-765 in Subjects With Treatment-Resistant Partial Epilepsy | ||
| NCT06886269 | A Study to Evaluate How the Body Processes 14C-VX-993 After a Single Oral Dose | ||
| NCT00966602 | Drug-Drug Interaction Study of VX-809 and VX-770 in Healthy Subjects | ||
| NCT02669849 | Study to Assess the Efficacy and Safety of VX-210 in Subjects With Acute Traumatic Cervical Spinal Cord Injury | ||
| NCT00916474 | Virology Follow up Study in Subjects Previously Treated With Telaprevir | ||
| NCT02565914 | A Study to Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Participants With Cystic Fibrosis Who Have an F508del-CFTR Mutation | ||
| NCT00780910 | Efficacy and Safety of MP-424, Peginterferon Alfa-2b, and Ribavirin in Patients With Chronic Hepatitis C Who Relapsed After Previous Interferon Based Therapy | ||
| NCT04702360 | ELX/TEZ/IVA Expanded Access Program for Cystic Fibrosis (CF) Patients With at Least One F508del Mutation | ||
| NCT06147778 | Performances and Safety of MuCopilot, a Digital Tool for the Unsupervised Objective Assessment of Cystic Fibrosis | ||
| NCT06926621 | A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dystrophy Type I | ||
| NCT00758043 | A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response | ||
| NCT01581138 | VX-222 + Telaprevir + Ribavirin for 12 or 16 Weeks in Treatment-Naive Subjects With Genotype 1a Hepatitis C | ||
| NCT07654296 | Assessing Suzetrigine for Pain Reduction Following Ureteroscopic Surgery | ||
| NCT05418712 | A Microneurography (MNG) Study of VX-150 in Healthy Participants | ||
| NCT05818852 | A Study to Evaluate the Effect of VX-548 on the QT/QTc Interval in Healthy Participants | ||
| NCT00627926 | A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV) | ||
| NCT01208285 | Study of VX-770 in Subjects With Moderate Hepatic Impairment and in Matched Healthy Subjects | ||
| NCT05704556 | Evaluation of the Pharmacokinetics and Safety of VX-548 in Participants With Renal Impairment | ||
| NCT03460990 | A Study of VX-659 Combination Therapy in CF Subjects Homozygous for F508del (F/F) | ||
| NCT02544451 | Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor | ||
| NCT04058353 | A Phase 3 Study of VX-445 Combination Therapy in Cystic Fibrosis (CF) Subjects Heterozygous for F508del and a Gating or Residual Function Mutation (F/G and F/RF Genotypes) | ||
| NCT02343445 | Clearing Lungs With Epithelial Sodium Channel (ENaC) Inhibition in Cystic Fibrosis (CF) | ||
| NCT03559062 | A Study to Evaluate Efficacy and Safety of TEZ/IVA in Subjects Aged 6 Through 11 Years With Cystic Fibrosis | ||
| NCT04786262 | A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes | ||
| NCT06619860 | Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy |
